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Human Amniotic Fluid-Derived Mesenchymal
Cells from Fetuses with a Neural Tube Defect
Do Not Deposit Collagen Type I Protein
After TGF-b1 Stimulation In Vitro
Nynke A. Hosper,1 Ruud A. Bank,1 and Paul P. van den Berg2
In spina bifida, the neural tube fails to close during the embryonic period. Exposure of the neural tube to the
amniotic fluid during pregnancy causes additional neural damage. Intrauterine tissue engineering using a
biomaterial seeded with stem cells might prevent this additional damage. For this purpose, autologous cells
from the amniotic fluid are an attractive source. To close the defect, it is important that these cells deposit an
extracellular matrix. However, it is not known if amniotic fluid mesenchymal cells (AFMCs) from a fetus with a
neural tube defect (NTD) share the same characteristics as AFMCs from a healthy fetus. We found that cells
derived from fetuses with a NTD, in contrast to healthy human amniotic fluid cells, did not deposit collagen type
I. Furthermore, the NTD cells showed, compared with both healthy amniotic fluid cells and fetal fibro-
blasts, much lower mRNA expression levels of genes that are involved in collagen biosynthesis [procollagen
C-endopeptidase enhancer proteins (PCOLCE), PCOLCE2, ADAM metallopeptidase with thrombospondin type
1 motif, 2 (ADAMTS2), ADAMTS14]. This indicates that NTD-AFMCs have different characteristics compared
with healthy AFMCs and might not be suitable for fetal therapy to close the defect in spina bifida patients.
Introduction
In open spina bifida (myelomeningocele), there is an in-complete closure of the neural tube at the end of the first
month of embryonic development. Neural tube defects
(NTD), one of the most common congenital malformations,
are associated with severe lifelong disabilities, including
mental impairment, paraplegia, urinary and fecal inconti-
nence, and skeletal deformities. Treatment of NTD consists of
closing the spinal lesion after birth (postnatal surgery),
thereby preventing infection. However, if detected during
pregnancy, fetal surgery can be performed to close the defect
[1–4]. It has been found that closure of the defect in utero
results in an improved outcome in select cases [4]. This has
been explained by the two-hit hypothesis: the failure of neural
tube closure (first hit) is followed by additional damage to the
neural tissue due to amniotic fluid exposure (second hit).
Repair in utero attenuates this secondary damage [1]. The
therapeutic potential of tissue engineering for prenatal NTD
coverage has been shown with collagen/gelatin scaffolds in
preclinical models [5–11]. So far, scaffolds loaded with cells
have not been used.
Amniotic fluid contains a population of mesenchymal
progenitor cells that can be used as a cell source for fetal
surgical therapy. This concept has been introduced about a
decade ago by the group of Fauza [12–19]. In short, some
congenital anomalies detected by prenatal imaging can, in
principle, be surgically treated with autologous amniotic
fluid mesenchymal stem cells (AFMCs). These cells can be
isolated and expanded from the amniotic fluid obtained from
amniocentesis. By seeding these cells in a scaffold, a fetus can
benefit from such an autologous graft in surgical procedures
aimed at repairing the congenital anomaly (fetal tissue en-
gineering) [20–23]. Several reports describe the differentia-
tion of the multipotent AFMCs into cell types such as
adipocytes, chondrocytes, osteoblasts, or smooth muscle cells
[24–31]. Cartilage and tendon grafts derived from AFMCs
have successfully been used in fetal repair efforts in large
animal models [14,18,19]. In a previous study, we showed
that AFMCs from healthy fetuses can be used to repair skin
defects [32].
Since the NTD coverage must be complete to prevent
leakage of amniotic fluid to the underlying tissues, we
questioned whether AFMCs can be used to accelerate the
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repair in utero. For future therapy, autologous AFMCs are
preferred, to reduce the chance of rejection. However, no
studies have been performed with AFMCs derived from fe-
tuses with a NTD; therefore, it is not known whether these
cells can be used for tissue engineering. In the current study,
we have investigated whether AFMCs from NTD fetuses can
be used as an autologous source for skin tissue engineering
by analyzing their ability to produce collagen type I and
therefore their capability of closing the defect.
In tissue engineering, mesenchymal progenitor cells need
to be differentiated into specialized cells to produce the re-
quired connective tissue (eg, chondrocytes to produce carti-
lage, or osteoblasts to produce bone). However, mesenchymal
progenitor cells have many fibroblast-like properties [33–36].
We hypothesized that a one-step procedure might be possible,
namely that amniotic fluid cells derived from a fetus with a
neural tube defect (NTD-AFMCs) can be placed in the bio-
material without performing a differentiation step, and that
these AFMCs subsequently produce a covering connective
tissue rich in collagen type I.
Materials and Methods
Cell culture
Confluent back-up human amniocentesis cultures were
received from the clinical cytogenetics laboratory of the
University Medical Center Groningen. Cells were cultured
from healthy fetuses (H-AFMCs, n= 4, with a normal kar-
yotype) and NTD-AFMCs (n = 4, with a normal karyotype) in
uncoated plates (Corning B.V. Life Sciences, Amsterdam, the
Netherlands). Cells were harvested and expanded in the
DMEM (Lonza, Breda, the Netherlands) supplemented with
20% fetal calf serum (FCS; Perbio Science, Etten-Leur, the
Netherlands) and 1% penicillin, 1% streptomycin (10,000U/
mL; Gibco, Paisley, United Kingdom), and 2mM L-gluta-
mine (Lonza). After passage 4, cells were cultured in the
DMEM supplemented with 10% FCS, 1% penicillin, 1%
streptomycin, and 2mM L-glutamine.
Primary fetal human dermal fibroblasts [HDF-f; Scien-
cell (#2300), Carlsbad, CA and Cell Applications (106-05f ),
San Diego, CA] were cultured in the DMEM supplemented
with 10% FCS, 1% penicillin, 1% streptomycin, and 2mM
L-glutamine.
Fluorescence-activated cell sorting
AFMCs (from passage 5–7) were incubated with FITC-
conjugated CD34 antibodies [1:10; IQ products (IQP-114F),
Groningen, the Netherlands], FITC-conjugated CD44 anti-
bodies [1:10; IQ products (IQP-118F)], FITC-conjugated
SSEA4 antibodies [1:10; Abcam (ab16287), Cambridge, Uni-
ted Kingdom], PE-conjugated CD45 antibodies [1:10; IQ
products (IQP-124R)], and PE-conjugated CD90 antibodies
[1:10; R&D systems (FAB2067P), Abingdon, United King-
dom] at 4C for 30min, followed by a wash step in PBS
containing 0.2% bovine serum albumin (BSA; Sanquin,
Amsterdam, the Netherlands). For Oct4 staining, cells were
first fixed with 2% paraformaldehyde (Merck, Darmstadt,
Germany) for 10min, permeabilized, and incubated with an
unconjugated Oct4 antibody [1:100; Abcam (ab19857)]
for 30min at 4C. Cells were washed and incubated for
15min with swine anti-rabbit TRITC (1:20; Dako, Glosstrup,
Denmark), followed by a wash step in PBS containing 0.2%
BSA. Cells were analyzed using a FACSCalibur system (BD
Biosciences, San Jose, CA). Data were analyzed by FlowJo
software (Tree Star, Ashland, OR).
Collagen I deposition by HDF-f, H-AFMCs,
and NTD-AFMCs after transforming growth
factor beta1 stimulation
HDF-f [ATCC (CCL-110), Manassas, VA], H-AFMCs, and
NTD-AFMCs were seeded at a density of 15,000/cm2 in
Permanox chamberslides (Nunc, New York, NY) in the
DMEM with 10% FCS. After 24 h, the medium was removed
and replaced with a medium containing 0.5% FCS and
50 ng/mL L-ascorbic acid 2-phosphate sesquimagnesium salt
hydrate (Sigma-Aldrich, Zwijndrecht, the Netherlands)
overnight. Subsequently, cells were exposed with or without
10 ng/mL recombinant human transforming growth factor
beta1 (TGF-b1; Peprotech, Rocky Hill, NJ) for 3 days, with
daily medium replacements.
After 3 days of culture (with or without TGF-b1), cells
were washed twice with PBS and fixed in 2% paraformal-
dehyde at room temperature for 10min. Fixed cells were
incubated with mouse anti-human collagen I [1:100; Abcam
(ab90395)] diluted in PBS containing 1% BSA for 1 h at
room temperature. After three washes with PBS, cells were
incubated with biotinylated goat anti-mouse IgG1 (1:100;
SouthernBiotech, Birmingham, AL) diluted in PBS con-
taining 1% BSA for 30min at room temperature. Then, the
cells were washed three times with PBS and incubated with
streptavidin-CY3 (1:400; Dako) in PBS containing 1% BSA,
2% normal human serum, and DAPI (1:5,000) for 30min.
After three washes with PBS, slides were mounted in Citi-
fluor (Agar Scientific, Stansted, United Kingdom) and
visualized using a Leica DMRA immunofluorescence mi-
croscope and Leica software (Leica Microsystems, Wetzlar,
Germany).
Gene expression analysis
HDF-f, H-AFMCs, and NTD-AFMCs (for all cell type
passages 5 or 6) were seeded at a density of 15,000/cm2 in
uncoated 6-well plates (Corning B.V. Life Sciences) in the
DMEM supplemented with 10% FCS, 1% penicillin, 1%
streptomycin, and 2mM L-glutamine. After 3 days of cul-
ture, total RNA was isolated from the cells using the RNeasy
Micro Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. Reverse transcription was carried
out using the First Strand cDNA synthesis kit (Fermentas, St.
Leon-Rot, Germany). Expression levels of genes known to be
involved in collagen biosynthesis and homeostasis (Table 1)
were analyzed with a custom made microfluidic card-based
low density array (Table 1; Applied Biosystems, Foster City,
CA) using the ViiA 7 Real-Time PCR System (Applied
Biosystems). For each sample, 100 ng cDNA was diluted in
50 mL of distilled water and mixed with 50 mL of TaqMan
PCR master mix (Applied Biosystems). Standard re-
commended PCR protocols were performed (50C for 2min,
95C for 10min, and the next two steps were repeated for 40
cycles: 95C for 12 s and 60C for 1min). Relative mRNA
levels were calculated as 2 -DCT, in which DCT is CT value of
target gene - CT value of GAPDH.
556 HOSPER, BANK, AND VAN DEN BERG
Statistical analysis
All data are represented as mean – standard error of the
mean of at least three independent experiments and were
analyzed by one-way ANOVA followed by the Tukey’s
post hoc analysis test using GraphPad Prism Version 5
(GraphPad Software, Inc., La Jolla, CA). Values of P< 0.05
were considered to be statistically significant.
Results
Characterization of amniotic fluid-derived cells
Human amniotic fluid cells contained a heterogeneous
cell population (containing cells with an epithelial and
mesenchymal morphology) at the first passage. After five
passages, all cells showed a mesenchymal phenotype. Cell
populations derived from both healthy fetuses (H) and fe-
tuses with a NTD showed a spindle-shaped morphology
(Fig. 1A). No differences were observed in morphology
between these two cell populations. For characterization,
amniotic fluid mesenchymal cells (AFMCs) were analyzed
by FACS for markers that are used for mesenchymal stem
cell characterization. Both cell populations were negative
( < 4% positive cells) for hematopoietic markers CD34
and CD45 (Fig. 1B). Furthermore, healthy and NTD-AFMCs
were positive for mesenchymal markers CD44 ( > 98%)
and CD90 ( > 65%) and embryonic stem cell markers
SSEA4 ( > 70%) and Oct4 ( > 94%). The expression pattern
of these markers indicates that both populations contain
predominantly amniotic fluid derived-mesenchymal stem
cells. No significant differences for all 6 markers were de-
tected between healthy and NTD-AFMCs, indicating that,
based on these markers, a similar cell population can be
isolated from healthy fetuses and fetuses with a NTD. This
suggests that NTD-AFMCs might be used for fetal tissue
engineering.
Collagen type I deposition by HDF-f, H-AFMCs,
and NTD-AFMCs after TGF-b1 stimulation
For skin tissue engineering, the formation of a new ex-
tracellular matrix (ECM) is a prerequisite. The most abun-
dant ECM protein in fetal skin is collagen type I, which is
produced by fetal fibroblasts. To stimulate collagen deposi-
tion by fibroblasts, the profibrotic cytokine TGF-b1 can be
used. We investigated whether TGF-b1 stimulation also in-
creases collagen deposition by AFMCs. Collagen type I de-
position was observed by HDF-f after 3 days of TGF-b1
stimulation (Fig. 2A), as was the case with H-AFMCs (Fig. 2B).
However, no collagen type I was deposited by NTD-AFMCs
(Fig. 2C). These results indicate that NTD-AFMCs fail to
produce mature collagen type I.
Expression pattern of genes involved
in collagen synthesis
Collagen biosynthesis is a complex process that involves
numerous modifying, folding and processing enzymes.
Differences in expression levels of these enzymes might
give an explanation as to why NTD-AFMCs are not able to
deposit collagen I protein. We investigated the expression
levels of genes that are involved in collagen biosynthesis
and homeostasis of HDF-f, H-AFMCs, and NTD-AFMCs
with a custom made microfluidic card-based low density
array.
Collagen synthesis starts intracellular with the synthesis of
a-chains of preprocollagen. Collagen type I is composed of a
triple helix, which consists of two identical a1 chains
(COL1A1) and one a2 chain (COL1A2). Healthy and NTD-
AFMCs show a similar expression of COL1A1 compared with
HDF-f (Fig. 3A). However, expression of COL1A2 in NTD-
AFMCs was very low (NTD-AFMCs have a 70- and 80-fold
lower expression compared with HDF-f (P< 0.05) and h-
AFMCs (P< 0.05), respectively). Collagen type III is composed
of a triple helix consisting of three a1 chains (COL3A1).
No significant differences were observed between HDF-f,
H-AFMCs, and NTD-AFMCs, although NTD-AFMCs showed
a sixfold lower expression of COL3A1 compared with HDF-f
(P= 0.128) and healthy AFMCs (P= 0.154). An important step
of collagen synthesis is the 4-hydroxylation of proline resi-
dues to obtain 4-hydroxyproline, this step involves the en-
zymes prolyl 4-hydroxylase, alpha polypeptide (P4HA) 1,
P4HA2, and P4HA3. No significant differences were found
Table 1. Composition of Low Density Array
Gene name Gene symbol Assay ID
Collagen type I, alpha 1 COL1A1 Hs00164004_m1
Collagen type I, alpha 2 COL1A2 Hs00164099_m1
Collagen type III, alpha 1 COL3A1 Hs00943809_m1
Prolyl 4-hydroxylase 1 P4HA1 Hs00914594_m1
Prolyl 4-hydroxylase 2 P4HA2 Hs00188349_m1
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in the expression of these genes between all three cell
types (data not shown). In collagen, certain lysine residues
can be hydroxylated by procollagen-lysine 1, 2-oxoglutarate
5-dioxygenase (PLOD) 1, PLOD2, and PLOD3 to form hy-
droxylysine. No significant differences were found in PLOD1
and PLOD2 expression levels, but PLOD3 is significantly
lower expressed by NTD-AFMCs compared with H-AFMCs
(P< 0.05) and HDF-f (P< 0.05) (Fig. 3B). Subsequently, some of
the hydroxylysine residues can be glycosylated. Galactose can
be added to the residues by glycosyltransferase 25 domain
containing 1 (GLT25D1) and GLT25D2. No differences were
found in the expression of these two genes between the cell
types (data not shown).
After hydroxylation of proline and lysine and glycosyl-
ation of hydroxyprolines, the three alpha chains assemble to
form the triple helix resulting in procollagen. Next, pro-
collagen is secreted and N- and C-propeptides are cleaved,
to form mature collagen. Bone morphogenetic protein 1
(BMP1), also known as procollagen C proteinase, cleaves
the C-propeptides of procollagen. No differences in BMP1
FIG. 2. Collagen type I de-




COL1A1 protein staining on
TGF-b1 stimulated HDF-f (A),
H-AFMCs (B), and NTD-
AFMCs (C) for 3 days. Origi-
nal magnification 200· .
COL1A1, collagen type I, al-
pha 1; HDF-f, fetal human
dermal fibroblasts; TGF-b1,
transforming growth factor
beta1. Color images available
online at www.liebertpub
.com/scd
FIG. 1. Characterization of
amniotic fluid-derived mesen-
chymal cells. (A) Morphology
of healthy and NTD-derived
amniotic fluid cells. Original
magnification 200· . (B) Per-
centage of positive cells
( – standard error of the
mean) of mesenchymal stem
cell markers determined by
FACS. No significant differ-




cells; NTD, neural tube defect;
NTD-AFMCs, amniotic fluid
cells derived from a fetus with
a neural tube defect.
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gene expression were found between HDF-f and AFMCs
(Fig. 3C). PCOLCE and PCOLCE2 are known to increase the
catalytic activity of BMP1. PCOLCE is expressed by HDF-f
and H-AFMCs, but was not expressed by NTD-AFMCs.
PCOLCE2 is much lower expressed in NTD-AFMCs and
H-AFMCs compared with HDF-f (both P< 0.001). The
N-propeptides are cleaved off from procollagens by the
metalloproteinases ADAMTS2, ADAMTS3, and ADAMTS14.
A significant lower expression of ADAMTS2 and ADAMTS14
(Fig. 3D) was observed in NTD-AFMCs compared with HDF-
f (P< 0.05) and H-AFMCs (P< 0.05). No differences were
found in ADAMTS3 expression. Overall, these results indi-
cate that NTD-AFMCs show impaired synthesis and proces-





FIG. 3. Expression pattern of genes involved in collagen synthesis. Gene expression levels of (A) COL1A1, COL1A2, and
COL3A1, (B) PLOD1, PLOD2, PLOD3, (C) BMP1, PCOLCE, and PCOLCE2, and (D) ADAMTS2, ADAMTS3, and ADAMTS14
in HDF-f, H-AFMCs, and NTD-AFMCs. *P < 0.05, ***P < 0.001. ADAMTS2, ADAM metallopeptidase with thrombospondin
type 1 motif, 2; ADAMTS3, ADAM metallopeptidase with thrombospondin type 1 motif, 3; ADAMTS14, ADAM metallo-
peptidase with thrombospondin type 1 motif, 14; COL1A2, collagen type I, alpha 2; COL3A1, collagen type III, alpha 1;
PLOD1, procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1; PLOD2, procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 2;
PLOD3, procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 3.
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Expression pattern of genes involved
in collagen degradation
Another explanation that NTD-AFMCs do not show col-
lagen protein deposition might be that secreted collagen is
quickly degraded by proteolytic enzymes. Therefore, we in-
vestigated the expression levels of enzymes that are involved
in matrix degradation (Fig. 4). Matrix metalloproteinase 1
(MMP1) expression is 10-fold lower in NTD-AFMCs
(P < 0.01) and 6.5-fold lower expressed in H-AFMCs (P < 0.01)
compared with HDF-f. The activity of MMPs can be in-
hibited by tissue inhibitor matrix metalloproteinase inhibitor
1 (TIMP1). No differences were found in TIMP expression.
Cathepsin K (CTSK) has been described to play a role in
dermal ECM turnover [37,38]. In this study, we show that
HDF-f and H-AFMCs express CTSK, but that is not ex-
pressed by NTD-AFMCs (P < 0.05).
These results indicate that the lack of collagen deposition
by NTD-AFMCs cannot be caused by an increased expres-
sion of enzymes with a collagenolytic activity.
Discussion
Neurological damage of spina bifida has been explained
by the two-hit hypothesis: the primary closure defect and
subsequent secondary damage due to exposure of neural
tissues [39–41]. Repair in utero, for example, by tissue engi-
neering techniques, can prevent this secondary damage
caused by the exposure to the intrauterine environment (eg,
the amniotic fluid). Several scaffolds have been used [5–11]
in tissue engineering approaches for treatment of spina bi-
fida, but always without the addition of AFMCs. In a pre-
vious study, we showed that healthy AFMCs can be used for
skin tissue engineering [32]. It might be possible to use these
healthy AFMCs for allogeneic cell therapy to treat spina bi-
fida, because the immature fetal immune system might be
less susceptible to immune rejection. However, the only
clinically successful in utero allogeneic stem cell therapy
using hematopoietic stem cells has been carried out in se-
verely immunologically compromised fetuses, suggesting
that the fetal immune system plays an important role in the
success of in utero stem cell therapy [42]. Therefore, autolo-
gous cell therapy is preferred. We stimulated NTD-AFMCs
with TGF-b1 (a cytokine that stimulates collagen produc-
tion), and compared the collagen type I deposition with that
of H-AFMCs and HDF-f. Surprisingly, NTD-AFMCs did not
show any collagen type I deposition, while both H-AFMCs
and HDF-f showed collagen I deposition after TGF-b1
stimulation. These comparisons of collagen deposition were
performed in monolayer cell cultures, under controlled TGF-
b1 stimulation. Possibly, the results could have been different
in vivo and/or under 3D conditions, both being more rep-
resentative of the biological process. In like manner, other
proteins of the TGF-b superfamily, other than TGF-b1, could
have led to different results.
The etiology of spina bifida is multifactorial; both envi-
ronmental and genetic factors play a role. So far, no muta-
tions have been causally linked to spina bifida in humans.
Folic acid deficiency due to nutrition problems is known to
be associated with a higher incidence of spina bifida [43].
Furthermore, a number of pharmaceutical compounds can
increase the risk of spina bifida [44,45]. The problem mani-
fests itself already at the first month after fertilization. Since it
is a highly localized defect, we expected that AFMCs derived
from these fetuses are normal, and that they can be used as
an autologous cell source for tissue repair purposes. How-
ever, much to our surprise, the NTD-AFMCs showed a
markedly different expression of genes that are related to
collagen synthesis compared with H-AFMCs and HDF-f. No
higher expression of enzymes that degrade collagen was
found in NTD-AFMCs, suggesting that collagen degradation
cannot explain the lack of collagen type I deposition (al-
though not all enzymes with collagenolytic activity were
studied), but that there might be a defect in collagen syn-
thesis and/or processing. Type I collagen is a heterotrimeric
molecule composed of two a1 chains and one a2 chain. NTD-
AFMCs did not express COL1A2. In addition, NTD-AFMCs
had a much lower expression of genes (PCOLCE, PCOLCE2,
ADAMTS2, and ADAMTS14) that are involved in the
cleavage of propeptides from procollagen. Failure to re-
move the N- and C-terminal propeptides might result in a
defective production of collagen fibrils. Despite the usage of
AFMCs in a variety of studies, the current knowledge about
the origin and function of these cells is limited. Therefore, it
is hard to explain why NTD-AFMCs show such a different
expression pattern of genes that are involved in collagen
biosynthesis. It might be possible that the mesenchymal
cells, which are isolated from fetuses with spina bifida,
represent an abnormal subpopulation that does no de-
posit collagen I, while the healthy collagen-producing
AFMCs possibly homed to the defect, as it has been shown
that AFMCs populated fetal wounds and that the actual
FIG. 4. Expression pattern of genes involved in collagen degradation. Gene expression levels of MMP1, TIMP1, and CTSK
in HDF-f, H-AFMCs, and NTD-AFMCs. *P < 0.05, **P < 0.01. CTSK, cathepsin K; MMP1, matrix metalloproteinase 1; TIMP1,
tissue inhibitor matrix metalloproteinase inhibitor 1.
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numbers of these cells can be affected by the presence of a
NTD [46,47].
In spina bifida, two different types of tissue are affected;
the nonclosure of the skin and the damaged neural tissue. In
principle, both tissues can be repaired by the use of tissue
engineering. Recently, in an experimental rat model for spina
bifida [48], it has been shown that neural stem cells were
present in the amniotic fluid derived from NTD rat fetuses,
but not in the amniotic fluid from control fetuses. Although
this has not been shown yet for humans, this could mean that
even when NTD-AFMCs are not able to produce collagen
(not suitable for skin tissue engineering, that is, closing the
defect), these cells might still be used for tissue engineering
to treat spina bifida to repair the neural tissue.
In summary, we have shown that NTD-AFMCs do not
deposit collagen type I protein in vitro. This can be explained
by a (much) lower expression of genes involved in collagen
synthesis and processing of these cells compared with
H-AFMCs and HDF-f. These results suggest that autologous
fetal therapy as treatment for spina bifida to close the defect
might not be possible.
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